Online inquiry

IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7979MR)

This product GTTS-WQ7979MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GHR gene. The antibody can be applied in Growth hormone (GH) deficiency research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000163.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2690
UniProt ID P10912
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7979MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3638MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ12446MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ1553MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ2606MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ5470MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ5491MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ10530MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ2363MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW